Axitinib,”effectively inhibits Bcr-Abl 1 (t315I) with a distinct binding conformationgood inhibitor of -S receptor; responds to release of vascular growth factorPeriodically monitor circulating DNA treated w/ Gleevec, and as soon as you see mutation

Axitinib,”effectively inhibits Bcr-Abl 1 (t315I) with a distinct binding conformationgood inhibitor of -S receptor; responds to release of vascular growth factorPeriodically monitor circulating DNA treated w/ Gleevec, and as soon as you see mutation

you have to switch over from Gleevec to Axitinib (drug repurposing)”